Clin Osteol 2014; 19(1): 10-15

CASE REPORT Secondary osteoporosis - a negative influence on the quality of life and survival of prostate cancer patiensCase reports

B. Špániková, J. Payer

Prostate cancer patients on antiandrogen therapy are at risk of bone loss, secondary osteoporosis development, pathological fractures and impaired quality of life. There is still very little attention paid to this group of patients. This fact is underlined by the presented case reports. In both cases, long-lasting androgen deprivation therapy led to vertebral compression fractures due to secondary osteo­ porosis. These fractures had a significant negative influence on the patients' quality of life. Antiosteoporotic therapy had excellent ef­ fects relieving pain and increasing bone density.

Keywords: prostate cancer, secondary osteoporosis, androgen deprivation therapy, antiosteoporotic therapy

Published: June 11, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špániková B, Payer J. CASE REPORT Secondary osteoporosis - a negative influence on the quality of life and survival of prostate cancer patiens. Osteologický bulletin. 2014;19(1):10-15.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Špániková B, Špánik S, Ondruš D. Osteoporóza pri chorobách závislých od hor­ mónov. Lek Obz 2010;59(11):449-452.
    2. Marcus R, Feldman D, Nelson DA, Rosen CJ. Osteeoporosis, Elsevier AP, Burlington MA, 2008:1939.
    3. Saad F, Adaclin JD, Brown JP, Canning LA, Getmon KA Pritchard KI. Cancer Treatement Induced Bone loss in Breast and Prostate Cancer. J Clin Oncol 2008; 20:5465-5476. Go to original source...
    4. Center JR, Nguyen TV, Schneider D. Mortality after all major types of osteopo­ rotic fracture in men and women: an observational study. Lancet 1999;353:878. Go to original source...
    5. Egerdie B, Saad F. Bone health in prostate cancer patients recieving androgen de­ privation therapy of present and future management option. Rew Canad Urolog Ass 2010;4:129-135. Go to original source...
    6. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;9:1001-1005. Go to original source...
    7. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation. Cancer 2006; 106:2530. Go to original source...
    8. Neville-Webbe HL, Gnant M, Coleman RE. Potential Anticancer Properties of Bisfosfonates. Sem Oncol 2010; 37, Suppl 1:53-65. Go to original source...
    9. Ellis GK. Denosumab FDA Review and Approval. J Clin Oncol 2008;26: 4875 4882. Go to original source...
    10. Smith MR, Saad F, Egerdie B. Effect of denosumab on bone mineral density in men recieving androgen deprivation therapy for prostate cancer. J Urol 2009; 182:2670-2676. Go to original source...
    11. Coleman RE, Abrahamson PA, Hadji P. Handbook of cancer-related bone disea­ ses. Bioscientifica 2010; pp.91-131.
    12. Coleman RE et al. Nat. Rev. Rheumatol. advance online publication 19 March 2013; doi:10.1038/nrrheum.2013.36. Go to original source...
    13. http://2013. www.nof.org
    14. Vestník MZ SR - Odborné usmernenie pre diagnostiku a liečbu osteoporózy 576/2004.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.